Published Date : 17 Apr 2023
The global PEGylation proteins market size was USD 1.74 billion in 2022, and it will grow at a rate of CAGR 10.95% in the years to come to touch around USD 4.92 billion by 2032.
The prevalence of chronic illnesses is rising, PEGylation demand is rising, and there are more potent new treatment options available, all of which are contributing to the growth of the PEGylation proteins market. Additionally, the sector is expected to expand as a result of PEGylated pharmaceuticals' enhanced protease protection, longer half-life, lower toxicity, and lower immunogenicity.
PEGylation is the method of connecting polymer chains to molecules or macrostructures, such as medications, therapeutic proteins, or vesicles. In the pharmacy industry, PEG is frequently referred to as macrogol. PEGylation alters how the resulting aggregates or derivatives interact, which frequently slows down the coalescence, disintegration, and in vivo removal of these compounds.
The forecast period will see the PEGylated Proteins Market expand as a result of increased biologics investments, an increase in the prevalence of chronic illnesses, and a preference for protein-based treatments over non-protein-based ones. The components are projected to drive the global market for PEGylated Proteins during that time.
The development of molecular biological engineering and biotechnology has led to an increase in the usage of protein-based therapeutics. Many treatments, including hormones, vaccines, growth factors, enzymes, and monoclonal antibodies, have seen an increase in demand during the last few years. Therapeutic advantages, including specificity and increased activity, have significantly increased biological availability and awareness among the affected population.
PEGylation Proteins Market Report Scope:
|Market Size in 2022||USD 1.74 Billion|
|Projected Forecast Value in 2032||USD 4.92 Billion|
|Growth Rate||10.95% from 2023 to 2032|
|Largest Market||North America|
|Forecast Period||2023 to 2032|
|By Product & Services||
|By End User||
|Regions Covered||North America, Europe, Asia-Pacific, Latin America and Middle East & Africa|
Throughout the forecast period, North America is anticipated to account for a sizable portion of the global PEGylated Protein market. The existence of significant players, the high prevalence of chronic diseases in the region, the developed healthcare infrastructure, and Americans' growing awareness of cutting-edge treatment options are some of the key factors influencing its sizeable market share. The presence of developed infrastructure and better economic conditions are driving an increase in grants and funding for biologics-based research activities. Its sizable market share is influenced by the region's high prevalence of chronic diseases, the nation's advanced healthcare system, and Americans' growing awareness of cutting-edge treatment options.
Two additional factors that are expected to drive market growth are beneficial government initiatives and an increase in research partnership numbers. For example, Nautilus joined Arya III, a special purpose acquisition company (SPAC), in February 2021 with an initial investment of USD 350 million to advance the development of its protein analysis technology for drug discovery and diagnostic applications.
On the other hand, The APAC region will grow at the fastest rate, according to the forecast. This industry, which is still growing, is known for emphasizing lowering labor and research costs. Low-cost research in densely populated countries like China, Japan, and India is expected to boost the region's growth. By 2032, China's market would hold the top spot in the Asia Pacific PEGylated Proteins Market by country. By 2021, China's market would dominate the region. It is anticipated that the CAGR for the Japanese market will be remarkable CAGR from 2022 to 2032. Additionally, the Indian market will display a notable CAGR throughout the projection period.
Projected Increase in the Colony-stimulating Factors Industry
By using colony-stimulating chemicals, blood cell production is sped up and function is enhanced. The activation of blood cells, which supports the immune system when a person is receiving cancer treatment, is influenced by these substances, even though they do not directly affect tumors. A half-dose of prophylactic granulocyte-colony stimulating factor (G-CSF) can safely and effectively prevent neutropenia in patients with various cancers who have an intermediate risk of febrile neutropenia (FN) combined with one patient-specific risk during chemotherapy.
However, the use of peptide cancer treatments and the rising incidence of cancer globally are the main factors driving the market growth for this segment. A March 2022 NCBI blog post states that China's cancer rates are rising. Lung cancer is the most common type of cancer in China, where 4,820,000 new cases are expected in 2022.
The market is expanding as a result of the increased demand for colony-stimulating agents to treat cancer, which is being caused by the rise in cancer incidence. Due to a growing understanding of the adverse effects of other cancer treatment modalities, such as chemotherapy and radiation therapy, among patients and healthcare professionals, there has been an increase in interest in complementary therapies, such as PEGylated peptide-based medications.
Failures in the discovery of drugs
Drug development is a difficult and complex process. It is uncommon for a medicine to be developed within the first trial due to the prevalence of drug development failures. Approximately 5% of drug development endeavors, including clinical development, fail. A costly drug failure may have a negative impact on pharmaceutical companies in the form of site closures, job losses, and reduced funding for R&D. As a result, over the projection period, the market for PEGylated proteins may face growth challenges due to ineffective medication development and an increase in therapeutic drug recalls.
PEGylated protein-based medicines are becoming more widely used
Throughout the projection period, the market expansion is anticipated to be aided by increasing acceptance of PEGylated protein-based therapeutics due to their higher stability and circulation half-life, as well as knowledge of ways to improve protein stability and circulation half-life. For instance, in September 2020, Maxwell Bioscience Co., Ltd. started a phase III clinical study to examine the immunogenicity, safety, and hemostatic efficiency of PEGylated recombinant FVIII (BAX 855) in patients who had not previously received treatment and met the criteria of being under the age of 6 and having severe hemophilia A.
Major Key Players:
Buy this Research Report@ https://www.precedenceresearch.com/checkout/2711
You can place an order or ask any questions, please feel free to contact at firstname.lastname@example.org| +1 9197 992 333